7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 500,230 | $356,328,836 | +88% | 0.26% |
| 2. | Squarepoint Ops LLC Maxime Fortin (Cio) | 254,579 | $181,344,259 | 0.17% | |
| 3. | Renaissance Technologies Jim Simons | 247,743 | $176,474,771 | +18% | 0.26% |
| 4. | 207,300 | $147,666,009 | +4% | 0.02% | |
| 5. | AQR Capital Management Cliff Asness | 207,085 | $147,096,307 | -9% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | 23,880,537 | 2017-08-25 | Filing | ||
| $485.99 | 2,681 | 23,877,980 | 2017-08-25 | Filing | ||
| $485.28 | 5,723 | 23,875,299 | 2017-08-25 | Filing | ||
| $484.21 | 2,000 | 23,869,576 | 2017-08-25 | Filing | ||
| $482.87 | 4,485 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $844.61 | 1,000 | Officer | 12,931 | 2024-11-01 | Filing | |
| $1,059.28 | 2 | Director | 17,582 | 2024-10-01 | Filing | |
| $1,057.38 | 2 | Director | 17,584 | 2024-10-01 | Filing | |
| $1,056.68 | 3 | Director | 17,586 | 2024-10-01 | Filing | |
| $1,054.90 | 3 | Director | 17,589 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,166 | $2,642,202 | 0.08% | |
| 2. | 897 | $568,904 | 0.43% | |
| 3. | 12,203 | $7,740 | 1.99% |
News See All
11 Blue Chip Stocks to Invest in at 52-Week Lows
For the first time since 2023, the S&P 500 was seen in the market correction territory, according to US Bank (Wealth Management).
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
11 Best Extremely Profitable Stocks to Buy According to Analysts
While the S&P 500 is hovering near correction territory, marking five years since its COVID-19 drawdown. Wyne noted that the risks appear evenly distributed between bullish and bearish outlooks.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Jim Cramer’s Latest Stock Moves: Top 10 Calls
Jim Cramer in a recent program on CNBC expressed his frustration over the recent market selloff following tariff uncertainties.
What Did Jim Cramer Say About These 19 Stocks Recently?
Jim Cramer kicked off his latest episode of Mad Money by highlighting the wild swings in the market, the ongoing trade war with Canada, and the growing concerns about tariffs and inflation.
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
11 Oversold Blue Chip Stocks to Buy According to Hedge Funds
The uncertainty related to the tariff announcements continues to influence Wall Street.
10 Worst Performing Large Cap Stocks to Buy According to Analysts
On January 21, Russell Investment released its Equity Factor report highlighting key trends and performances in global equity markets during the fourth quarter of 2024.
Billionaire Hedge Funds
